Series of 1-(N-phenyl-2-(heteroalicyclic-1-yl)acetamido)cyclohexane-1-carboxamide derivatives (5a-m) and 1-(phenyl(heteroalicyclic-1-ylmethyl)amino)cyclohexane-1-carboxamide (6a-f) were designed and synthesized with biological interest through coupling of 1-(2-chloro-N-phenylacetamido)cyclohexane-1-carboxamide (4) and (phenylamino)cycloakanecarboxamide (2) with different amines. The structures of the target compounds were elucidated via IR, 1 H and 13 C NMR, MS, and microanalysis. Compounds 5a-m and 6a-f were evaluated for their in vitro antitumor activity against four different cancer cell lines, MCF-7, HepG2, A549, and Caco-2. Compound 5i exhibited a promising activity against breast cancer cell line (IC 50 value = 3.25 μM) compared with doxorubicin (IC 50 value = 6.77 μM). Results from apoptosis and cell cycle analysis for compound 5i revealed good antitumor activity against MCF-7 cancer cell line and potent inhibition.
INTRODUCTION
Cancer is one of the most prominent diseases worldwide which represents the second cause of human mortality after cardiovascular diseases 1 . Drug resistance to cancer chemotherapy is considered a serious trouble 2 . Thus, there is a critical need for new chemotherapeutic agents 3, 4 . The cyclohexane core generally has enriched the medicinal chemistry armamentarium with several bioactive candidates having diverse biological activities such as antipsychotic 5 , expectorant 6 , anticonvulsant 7, 8 , analgesic 9 and anticancer activities [10] [11] [12] . Etoposide (I) and Teniposide (II) contain cyclohexane moiety in their structures and are used in cancer chemotherapy for the treatment of lung cancer, acute leukemia and lymphoma through a cytotoxic mechanism of DNA-topoisomerase II inhibition [13] [14] [15] . Moreover, the aminoacyl pharmacophore chain and amide moiety were included in the structural frame of different antitumor compounds, III and IV (Fig. 1 ), which were found to possess antitumor activity [16] [17] [18] [19] .
These findings have encouraged us to prepare the target compounds 5a-m and 6a-f through molecular hybridization tactic of two or more pharmacophore moieties in one molecule aiming to improve the pharmacological profile 
Fig. 1. (A) Structures of Etoposide (I) and Teniposide (II); (B) Antitumor biocandidates bearing aminoacyl moieties; (C) target compounds containing the pharmacophoric features

RESULTS AND DISCUSSION
Chemistry
The preparation of the ultimate compounds 5a-m and 6a-f as well as the intermediates 1-4 is illustrated in Scheme 1. Cyclohexanone was reacted with potassium cyanide and aniline in glacial acetic acid to produce the nitrile derivative 1 which was hydrolyzed using sulfuric acid at room temperature to produce the amidic compound 3.
The penultimate intermediate 4 was achieved by acetylation of compound 3. Subsequently, compound 4 was subjected to the reaction with different amines to afford 5a-m, while compound 3 was reacted with formaldehyde and different amines to afford 6a-f.
Reagents and conditions: i) Cyclohexanone, potassium cyanide, acetic acid glacial, r.t, 24 h ii) H 2 SO 4 , r.t, 48 h, iii) ClCOCH 2 Cl, CHCl 3 , r.t , 24 h, iv) ethanol, appropriate amine, 12 h, reflux v) HCHO, ethanol, appropriate amine, 12 h, reflux.
Biological Evaluation Antiproliferation assay
The antitumor activity for compounds 5a-m and 6a-f were evaluated against the four cancer cell lines HepG2 (liver), MCF-7 (breast), A549 (lung) and Caco-2 (colorectal). Results are illustrated in (Table 1 
Cell cycle analysis and apoptosis induction
Compound 5i was the most potent against MCF-7 cancer cell line. Consequently, we examined its effect on the cell cycle progression using BD FASCCalibur after treatment with 3.25 μM of 5i for 48 h. Then, cell was stained with an annexin V-FITC antibody and propidium iodide by FACS (Table 2 ). For the cell cycle, compound 5i revealed induction of apoptosis at pre G1 phase and arresting at G2/M phase. Mass spectral data were gained using the technique of electron impact (EI) ionization. Column chromatography was conducted using silica gel 60 and chloroform/methanol 9/1 (v/v) as a mobile phase.
Synthesis of 1-(phenylamino)cyclohexanecarbonitrile (2)
Compound 2 was prepared as showed in literatures 8 .
Synthesis of (phenylamino)cycloakanecarboxamide (3)
Compound 3 was prepared as showed in literatures 8 .
Synthesis of 1-(2-chloro-N-phenylacetamido) cyclohexane-1-carboxamide (4)
Chloroacetyl chloride (1.317g, 0.95 mL, 0.01166 mol) was added to a solution of 3 (2.1g, 0.0097 mol) in chloroform (30 mL). The mixture was allowed for stirring at room temperature for 24 h, then adding an aqueous solution of 10% NaOH (2 x 30 mL) then separation of the organic layer, drying over anhydrous Na 2 SO 4 and evaporation under reduced pressure to afford 2.5 g of 4 as pale yellow oil in 89.2% yield which is solidified upon standing at room temperature, m. 
General procedure for the synthesis of 1-(N-phenyl-2-(heteroalicyclic-1-yl)acetamido)-cyclohexane-1-carboxamides (5a-m)
To a solution of 4 (1.32 g, 0.0045 mol) in ethanol (30 mL), the appropriate amine derivative (0.0135 mol) was added. Then the reaction was refluxed under stirring for 12 h, and then ethanol was evaporated under reduced pressure. The residual was dissolved in ethyl acetate (30 mL) and washed with water (3x30 mL) then separation of the organic layer, drying over anhydrous Na 2 SO 4 and evaporation under the reduced pressure to produce 5a-m. Imidazol-1-yl)-N-phenylacetamido -2-(piperazin-1-yl) Methylpiperazin-1-yl)-N-phenylacetamido 
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Biological Evaluation
The human tumor cell lines were obtained from NCI, MD, USA. All chemicals and solvents were purchased from Sigma-Aldrich.
Cell proliferation assay
The anticancer activities for compounds 5a-m and 6a-f were performed using a standard (MTT)-based colorimetric assay 21 .
Cell Cycle Analysis and Detection of Apoptosis in MCF-7 cell line
Studying the effect of compound 5i on the cell cycle progression using BD FASC Calibur after treatment with 3.25 μM of 5i for 48 h. Then, cell staining with an annexin V-FITC antibody and propidium iodide by FACS 22 .
CONCLUSION
Series of 1-(N-phenyl-2-(heteroalicyclic-1-yl) acetamido)cyclohexane-1-carboxamide derivatives (5a-m) and 1-(phenyl(heteroalicyclic-1-ylmethyl)amino) cyclohexane-1-carboxamide (6a-f) have been synthesized and screened for their anticancer activity. Compound 5i exhibited the most potent anticancer activity. It inhibited the MCF-7 cell line with IC 50 value of 3.25 μM inducing apoptosis at PreG1 and arrested of the cell cycle at G2/M phase.
